Clinigen acquires global rights to Proleukin outside US
Financial details have not been disclosed. Proleukin® is licensed in around 20 countries around the world and is primarily indicated for use in metastatic renal cell carcinoma, as
Genialis has teamed up with Inventia Life Science to enhance the testing of pancreatic cancer treatments and match them to the patients who are likely to benefit.
Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president